Bethesda, MD—Physicians may now be better at detecting breast cancer than ever before, but much more work remains to ensure accurate diagnosis is possible and especially to assess future risk. That's why researchers from Germany have been working to develop a new test of gene action to predict cancer risk both at first diagnosis and into the future. In a new research report appearing in the December 2012 issue of The FASEB Journal, researchers show that the various genetic switches, which are turned on and off in the regular development of every cell in the body, can be analyzed in minute detail to determine the presence or risk of breast cancer growth.
"We hope that our results help to develop tools to identify breast cancer patients when tumors are still small, and eventually curable," said Clarissa Gerhauser, Ph.D., a researcher involved in the work from the Division of Epigenomics and Cancer Risk Factors at the German Cancer Research Center in Heidelberg, Germany. "These tools might hopefully also help to predict the progression of tumor development and guide decisions on cancer treatment."
To make this advance, Gerhauser and colleagues extracted DNA from 10 small tumor tissue samples and 10 normal breast tissues from breast cancer patients. They made small fragments from the extracted DNA and identified the genetic switches within those fragments. By comparing the results from various combinations of DNA fragments, scientists discovered which switches were more prevalent in tumor tissue than in normal breast tissue. The methods used to quantify the switches are extremely sensitive, making it feasible that small biopsies would be sufficient for analysis and testing.
"This is a milestone. The method described detects activity at the genetic level, which often occurs well before any outward symptoms occur," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Not only could this allow for earlier diagnosis of breast cancer and more accurate risk assessment, but eventually, this technique might be used in other types of cancer as well."
Receive monthly highlights from The FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). It is among the most cited biology journals worldwide according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century. FASEB is composed of 26 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. Celebrating 100 Years of Advancing the Life Sciences in 2012, FASEB is rededicating its efforts to advance health and well-being by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Details: Marta Faryna, Carolin Konermann, Sebastian Aulmann, Justo Lorenzo Bermejo, Markus Brugger, Sven Diederichs, Joachim Rom, Dieter Weichenhan, Rainer Claus, Michael Rehli, Peter Schirmacher, Hans-Peter Sinn, Christoph Plass, and Clarissa Gerhauser. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J 26:4937-4950, doi:10.1096/fj.12-209502 ; http://www.fasebj.org/content/26/12/4937.abstract
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.